PrintDRUG DEVELOPMENT
Amgen's 15-Year Effort to Build a Blockbuster
Podcast: June 14, 2010The Burrill Report (June 14, 2010): Amgen's 15-Year Effort to Build a Blockbuster (.MP3,14.8 Mb)
Amgen’s denosumab, its treatment for osteoporosis, has won approval in both Europe and the United States. Marketed under the name Prolia, analysts forecast sales will approach $1 billion in 2011 and EvaluatePharma thinks that could grow to $5.3 billion by 2016. We spoke to Dave Lacey, senior vice president and head of research for Amgen, about the long road travelled to bring Prolia to market, why the discovery and development of new drugs like it remains so difficult, and what other interesting therapies might be working their way through Amgen’s deep pipeline.
[Please login to post comments]
- Pfizer Targets Rare Diseases
Drug giant forms new unit to pursue uncommon, but lucrative, patients. Read More - Pfizer cuts Trubion program loose
Drug giant dumps one of the biotech's experimental rheumatoid arthritis drugs after mid-stage trial results fail to excite. Read More - Adapting for Success
Video: The BioConference Live interview with G. Steven Burrill from June 3, 2010. Read More - Blaming Genes
Adults are more likely to give too much importance to genetic causes of disease rather than addressing lifestyle, study finds. Read More - Forest Diabetes Deal
Pharma company gains access to Transtech's new class of compounds in deal that could total $1.1 billion. Read More - Grifols' Taste for Blood
Spanish company offers $3.4 billion for Talecris. Read More - FDA Panel Gives Novartis MS Drug Thumbs Up
Positions Swiss drugmaker in the lead to bring an oral multiple sclerosis treatment to the market. Read More - Watching Where You Eat
Video study finds risky food-safety behavior more common than thought. Read More - Talecris Offers Private Equity Backers a Big Payday
Grifols $4 billion package leads a hot week for life sciences deals. Read More - A Cheap Fix
Forty-year-old gout drug Allopurinol could be used to treat angina. Read More
.gif)
.gif)
- The Path to Personalized Medicine
The New England Journal of Medicine - FDA, NIH lay out roadmap for personalized medicine
Reuters - Inexpensive Drug May Save 100,000 Lives a Year After Accidents
Bloomberg - Awaiting the Genome Payoff
The New York Times - A Dirt-Poor Nation, With a Health Plan
The New York Times - Teenage boys really do eat a lot: study
Reuters Health - Drug-resistant bugs on rise globally: report
Reuters - President of J&J;’s Unit Said to Have Urged Unpublicized Recall
Bloomberg - U.S. court grants injunction against Dr Reddy's
Reuters - Key cuts to healthcare waste saves $3.6 trillion
Reuters